Entropy Technologies LP Invests $1.06 Million in Danaher Co. (NYSE:DHR)

Entropy Technologies LP acquired a new stake in shares of Danaher Co. (NYSE:DHR) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 4,241 shares of the conglomerate’s stock, valued at approximately $1,059,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Cape Investment Advisory Inc. bought a new position in shares of Danaher in the fourth quarter valued at approximately $25,000. Tsfg LLC boosted its stake in Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares in the last quarter. BKM Wealth Management LLC acquired a new position in shares of Danaher during the 4th quarter valued at $27,000. Wetzel Investment Advisors Inc. bought a new stake in shares of Danaher in the 4th quarter worth $29,000. Finally, Redmont Wealth Advisors LLC acquired a new stake in shares of Danaher in the first quarter valued at $30,000. 79.05% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on DHR shares. Jefferies Financial Group began coverage on Danaher in a report on Monday, June 3rd. They set a “buy” rating and a $295.00 target price on the stock. HSBC raised shares of Danaher from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $250.00 to $280.00 in a research note on Wednesday, April 17th. TD Cowen raised their target price on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Barclays upped their price target on Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a report on Wednesday, April 24th. Finally, Bank of America raised their price objective on Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 24th. Six analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $268.67.

Danaher Stock Down 0.3 %

Shares of DHR traded down $0.87 during midday trading on Wednesday, reaching $251.27. 2,718,484 shares of the stock were exchanged, compared to its average volume of 2,857,297. The company has a market cap of $186.11 billion, a price-to-earnings ratio of 42.59, a P/E/G ratio of 3.76 and a beta of 0.83. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $269.11. The firm has a 50 day simple moving average of $255.09 and a 200-day simple moving average of $247.90.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.20. The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The company’s revenue for the quarter was down 2.6% on a year-over-year basis. During the same quarter last year, the firm earned $2.36 earnings per share. Research analysts forecast that Danaher Co. will post 7.63 EPS for the current year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.43%. The ex-dividend date of this dividend is Friday, June 28th. Danaher’s dividend payout ratio is presently 18.31%.

Insider Buying and Selling at Danaher

In other news, CEO Rainer Blair sold 9,005 shares of the company’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the completion of the sale, the chief executive officer now owns 106,990 shares in the company, valued at approximately $28,352,350. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Danaher news, CFO Matthew Mcgrew sold 46,377 shares of the company’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $253.05, for a total transaction of $11,735,699.85. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares in the company, valued at $7,441,441.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Rainer Blair sold 9,005 shares of Danaher stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $265.00, for a total value of $2,386,325.00. Following the completion of the transaction, the chief executive officer now owns 106,990 shares in the company, valued at $28,352,350. The disclosure for this sale can be found here. Insiders have sold a total of 148,783 shares of company stock worth $37,536,717 over the last three months. Corporate insiders own 11.10% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.